BioTarget DX

Overview

BioTarget DX is building the next generation of liquid biopsy and infectious disease diagnostics—scalable, point-of-care (POC) platforms targeting multi-billion-dollar markets. Backed by multiple issued patents, NCI funding, and decades of translational research leadership, we are uniquely positioned to drive commercialization through strategic partnerships, licensing, and investment.